QazCovid-in

Part of a series on the
COVID-19 pandemic
COVID-19 (disease) SARS-CoV-2 (virus) Cases Deaths
Timeline 2019 2020 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November responses December responses 2021 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November responses December responses
Locations By country and territory Africa Antarctica Asia Europe North America Oceania South America By conveyance Cruise ships Naval ships
International response Evacuations Face masks International aid Investigations into origin Lockdowns Misinformation By governments China US Fake treatments Protests US Software Travel restrictions United Nations World Health Organization WTO IP waiver Undercounting of deaths National responses Africa European Union Germany Ghana India New Zealand Nigeria Philippines Russia Sweden UK government US federal government Vietnam
Medical response Disease testing Breathalyzer Development Drug development Drug repurposing Vaccines History Research VITT Deployment Authorizations Operation Warp Speed Misinformation and hesitancy US Vaccine card Vaccine passports CoronaVac Covaxin Convidecia Janssen Moderna Oxford–AstraZeneca Pfizer–BioNTech Sinopharm BIBP Sputnik V
Variants Variants of concern Alpha Beta Gamma Delta Omicron Other variants Epsilon Zeta Eta Theta Iota Kappa Lambda Mu Cluster 5 Lineage B.1.617
Economic impact and recession Arts and culture Aviation Cannabis Cinema films Disney Fashion Financial markets Food industry Canadian meat US meat Food security Journalism Music Performing arts Retail Shipping Sports Ireland Philippines Television US programs Tourism Video games By country Canada India Ireland Malaysia New Zealand Russia UK US
Impacts Animals Black people Crime Ireland Death rates by country Disability Domestic violence Emergency evacuations Education Female Ghana Ireland UK US Environment Hospitals Language LGBT community Long-term care Mental health Symptoms Migration Military Notable deaths South Africa Other health issues Politics Ireland Malaysia Russia Popular culture Protests Pregnancy Prisons Religion Catholic Church Hajj Science and technology Social media Society Ireland Malaysia New Zealand Russia UK US Strikes Suicides Telehealth Xenophobia and racism
COVID-19 portal
v t

QazCovid-in, commercially known as QazVac,^[1][2] is a COVID-19 vaccine developed by the Research Institute for Biological Safety Problems in Kazakhstan.^[3][4] QazCoVac-P is a second COVID-19 vaccine developed by the Kazakh Biosafety Research Institute and in clinical trials.^[5]

Manufacturing[]

The vaccine can be stored at standard refrigeration temperatures (2°C-8°C) and is a two-dose régime with the doses administered twenty-one days apart.^[6]

The vaccine was first manufactured by Kazakhstan's Research Institute of Biological Safety Problems. Production capacity has been capped at 50,000 doses per month.

Beginning in June 2021, the vaccine is slated^[7] to be packaged in large bulk to be bottled in Turkey by a major Turkish company.^[8][9] This will allow for a production capacity of 500,000-600,000 doses per month.^[10] The contract is still being negotiated,^[11] despite earlier claims suggesting that the deal had already been finalized.^[12][13]

In October 2021, it was announced that the vaccine would be supplied to Afghanistan and other countries in 2022.^[14]

History[]

Clinical trials[]

In September 2020, QazVac started in Phase I/II clinical trials.^[15]

In December 2020, QazVac is currently in Phase III clinical trials, which is expected to be fully completed by 9 July 2021.^[16][17] It is unclear when the first preliminary results will be published.^[18][19]

The administration of the vaccine for the general population began at the end of April 2021.^[20] The Research Institute Kunsulu Zakarya's Director General's justification is that the trial is almost 50% completed and "people who have received [the] vaccine feel well; there have been no side-effects and the effectiveness of the vaccine is high".^[21]

In September 2021, a study was published to EClincicalMedicine, published by The Lancet. The study’s finidings were that the “QazCovid-in® vaccine was safe and well-tolerated and induced predominantly mild adverse events; no serious or severe adverse events were recorded in both trials.” ^[22]

Authorization[]

Economics[]

The first batch of 50,000 doses was delivered on 26 April 2021, and vaccination began shortly after.^{[citation needed]} In June 2021, the capacity will increase to 100,000 doses per month, regardless of the contract for bottling in Turkey.^[23]

References[]

External links[]

Scholia has a profile for QazCovid-in (Q99518269).